RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, April 19, 2006, titled, "Ranbaxy Q1, 06, Global Sales at USD 287 Mn, up 14 per cent - Board recommends final dividend of Rs. 6 per share" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 30, 2006, titled, "RANBAXY ACQUIRES ETHIMED IN BELGIUM - Offers Ranbaxy strategic market access and distribution network for Benelux countries". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 29, 2006, titled, "Ranbaxy Acquires Leading Romanian Pharma company Terapia for US $324m - Major Strategic Step in expanding European operations - New entity will be the largest generic company in Romania". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 27, 2006, titled, "Ranbaxy to Acquire the Unbranded Generic Business of Glaxosmithkline in Italy." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 24, 2006, titled, "Ranbaxy Launches Osonide Inhaler for the treatment of Asthma; Novel product introduced for the First time in India." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated, March 21, 2006, titled, "RANBAXY PURCHASES RIGHTS AND ASSETS TO SENETEK'S AUTOINJECTOR DEVICE', being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated, March 09, 2006, titled, "Ranbaxy enters into a strategic alliance with Zenotech - Agreement heralds Ranbaxy's entry into the Oncology segment in LATAM, Russia & other CIS markets', being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, February 16, 2006, titled, "Ranbaxy Laboratories Limited places US$ 400 million Foreign Currency Convertible Bonds; Single largest capital raising by an Indian healthcare company." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has clarified that there have been several recent press reports speculating about potential acquisitions that may be made by the Company. The Company has previously stated that part of its strategy is to grow through acquisitions. From time to time the Company may consider a range of acquisitions and may make bids in competitive tenders. The details of the press release issued by the company on February 15, 2006 in this regard shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announceme

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 06, 2006, titled "Ranbaxy Forms Joint Venture in South Africa to Supply ARV Medicines for Africa Market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated, January 24, 2006, titled, " Ranbaxy Launches Volix (VOGLIBOSE) for the treatment of Diabetes; Product introduced for the first time in India." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 18, 2006, titled "Brian Tempest promoted as Chief Mentor and Executive Vice Chairman Malvinder Mohan Singh takes charge as CEO and MD in smooth succession plan." The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 18, 2006, titled " Ranbaxy Year 2005 Global Sales at USD 1178 MN." The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 10, 2006, titled "Ranbaxy to co-market Ferring's Urology drug in India Treatment to benefit Paediatric and Geriatric Nocturia patients." The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company dated January 02, 2006 titled "RANBAXY'S TOANSA PLANT RECEIVES NATIONAL AWARDS FOR EXCELLENCE IN WATER MANAGEMENT". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the company dated December 23, 2005 titled "Ranbaxy Laboratories Limited Announces an Agreement with Cephalon Regarding Settlement of Provigil� Patent Litigation; Parties Also Agree to Business Arrangements Related to Modafinil". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 17, 2005 titled "Ranbaxy to Appeal U.S. District Court Decision Upholding Pfizer Atorvastatin Patents". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 13, 2005 titled "Promising New Antimalarial Drug Demonstrates Significant Parasite Reduction in Patients". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 01, 2005 titled "Ranbaxy ready to help the U.S. Government to meet the Avian Flu Challenge". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 30, 2005 titled "Ranbaxy launches two new Anti-HIV products in India on World AIDS Day". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 28, 2005 titled "RANBAXY HONOURS INDIAN SCIENTISTS FOR OUTSTANDING RESEARCH CONTRIBUTIONS - RESEARCH AWARDS FOR THE YEAR 2004 PRESENTED". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has issued a press release dated November 23, 2005 titled "US Court of Appeals Uploads Preliminary Injunction Against Ranbaxy, Enjoining Company From Marketing Quinapril HCL Tablets - Case Moves to Trial in District Court". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release titled 'RANBAXY CONSOLIDATES RELATIONSHIP WITH JAPAN JV PARTNER NIPPON CHEMIPHAR; Equal partnership to reflect increased co-operation between both companies', being issued by the Company on November 11, 2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: corporates > latest announcements and on the extranet server (/common/corporateannouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 11, 2005 titled "US COURT DECISION PROVIDES CLARITY FOR LAUNCH OF RANBAXY'S CLARITHROMYCIN 500 MG EXTENDED RELEASE (ER) TABLETS UPON APPROVAL - Court rules in favour of Ranbaxy on two of three patents on Clarithromycin 1000 mg ER product". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release which is being issued by the Company dated November 10, 2005 titled 'Ranbaxy wins on atorvastatin process patent in Norway - will appeal Court ruling on intermediate compound patent.' The details of the press release shall be available on the nse website (http://www.nseindia.com) under: corporates > latest announcements and on the extranet server (/common/corporateannouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 03, 2005 titled " Ranbaxy granted permission to appeal U. K. High Court Judgement on patent relating to Atorvastatin ". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 31, 2005 titled "Ranbaxy Clarifies 180 day Exclusivities relating to Pravastatin 80mg and Simvastatin 80mg Tablets." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release being issued by the company dated October 27, 2005 titled, "Ranbaxy and Promotor group companies fortis healthcare, fortis securities & the escorts heart Institute & Research centre contribute Rs.1 crore in cash and essential medicines for Kashmir quake victims." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the Company dated October 21, 2005, titled 'Ranbaxy Q3 Global Sales at USD 298 mn, up by 2% board approves interim dividend of 50% (Rs.2.50 per share)'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated October 19, 2005 titled, "Ranbaxy's Antimalarial Molecule Successfully Completes POC Phase II Studies", being issued by the company.' The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 12, 2005, titled "U.K. High Court rules in favour of Ranbaxy over one key atorvastatin patent, but says its product infringes another. Ranbaxy to appeal", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 13, 2005, titled "Ranbaxy files suit against Barr Laboratories and Teva Pharmaceuticals USA", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 10, 2005, titled "Ranbaxy Gains Final Approval From USFDA To Manufacture and Market Gabapentin Capsules", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 07, 2005, titled "Ranbaxy Receives Final Approval From US FDA To Market Glimepiride Tablets", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 30, 2005, titled "Another Ranbaxy ARV Pre-Qualified by WHO". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued by the Company dated September 29, 2005, titled "Ranbaxy gains approval to market Pseudoephedrine Hydrochloride Extended-Release Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that a press release is being issued by the Company on September 27, 2005, titled "Ranbaxy to market Lupin's tuberculosis brands in severely affected West & North African markets." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 22, 2005, titled 'Ranbaxy launches in Canada - India's largest pharmaceutical company to bring high quality, affordable drugs to Canada.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on September 20, 2005, titled "Ranbaxy receives approval from USFDA to Market Zidovudine tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 19, 2005, titled "RANBAXY RECEIVES TENTATIVE APPROVAL FROM USFDA TO MARKET TOLTERODINE TARTRATE TABLETS", being issued by the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 16, 2005, titled "RANBAXY RECEIVES FINAL APPROVAL FROM USFDA FOR GABAPENTIN TABLETS", being issued by the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 13, 2005, titled "RANBAXY LAUNCHES ITALIAN OPERATIONS; Now present in all top five pharmaceutical markets in Europe and 21 of 25 EU countries", being issued by the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated September 07, 2005, titled "Ranbaxy provides Relief Services to Victims of Hurricane Katrina". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 2, 2005, titled "RANBAXY TO FOCUS ON PHARMACEUTICALS BUSINESS; Reaches an understanding with potential buyers to divest its Allied Businesses", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 25, 2005, titled "RANBAXY RECEIVES PRESTIGIOUS SUPPLIER QUALITY AWARD FROM CARDINAL HEALTH; Second major supplier award for Ranbaxy this year following the earlier prestigious award from Wal-Mart", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on August 16,2005 titled " Ranbaxy opens third state of the art R&D facility on Gurgaon campus to focus on NCE discovery research". The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has announced on August 11, 2005, that the World Health Organisation (WHO), Geneva, has included the Company's seven Anti Retrovirals (ARVs) in its pre-qualification list. The details of the press release issued by the Company regarding the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 28, 2005, titled "Ranbaxy Gains Tentative approval to market additional strengths of Glimepiride Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on July 28, 2005, titled "Ranbaxy Global Sales at USD 309 MN, Records 11% growth". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release being issued on August 03, 2005, titled "Ranbaxy receives tentative approval to market Sumatriptan Succinate Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).